Abeona Therapeutics(ABEO) - 2025 Q1 - Quarterly Results

Exhibit 99.1 Abeona Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates - Received approval by U.S. Food and Drug Administration (FDA) for ZEVASKYN™ (prademagene zamikeracel), the first and only autologous cell-based gene therapy for the treatment of wounds in adult and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB) - - U.S. launch of ZEVASKYN underway with activation of first qualified treatment center (QTC) - - Entered into sales agreement for priorit ...